LONDON, UK / ACCESSWIRE / October 10, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=INSY. The Company announced on October 06, 2017, that it would like to reiterate that it continues to work with relevant authorities to resolve issues related to inappropriate actions taken by some of its former employees. INSYS stated that it has undertaken a series of major actions to prevent the issue arising again in the future. INSYS is a specialty pharmaceutical company that develops and commercializes drug and novel drug systems of therapeutic models that improve the patient’s quality of life. For immediate access to our complimentary reports, including today’s coverage, register for free now at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on INSY. Go directly to your stock of interest and access today’s free coverage at:
The Company made this announcement with respect to the complaint filed by the New Jersey Attorney General on October 05, 2017. New Jersey accused INSYS of engaging in a fraudulent scheme to boost sales of a fentanyl-based cancer pain drug. The lawsuit by Christopher Porrino, New Jersey’s Attorney General, states that INSYS illegally directed its sales force to push prescriptions of Subsys for a wide range of patients that the opioid drug was approved to and at doses higher than the permissible limits.
INSYS has been facing a similar lawsuit from Massachusetts’ Attorney General, Maura Healey, where INSYS would pay $500,000 to resolve similar allegations. Healey once stated that Fentanyl is a powerful and highly addictive drug with fatal consequences. However, INSYS aggressively marketed its product and made illegal payments to boost sales.
INSYS announced that the Company is under new management and has replaced 90% of the original sales force and commercial organization. The Company stated that it finds the lawsuit understandable, yet disingenuous, for a firm that has been taking steps to conduct business according to standards. The Company also finds the lawsuit unfair to its current employees, a majority of which are new to INSYS and had no involvement in the previous cases.
The Company stated that it currently employs over 400 people and has invested over $250 million over the past 5 years in research and development (R&D), which enables delivery of new treatment options for unmet medical needs. INSYS has been constantly placed at the center of investigations, focused on Subsys, an under-the-tongue spray intended for cancer patients that contains fentanyl, a highly addictive synthetic opioid.
Company Growth Prospects
Prior to the announcement, on October 03, 2017, the Company reported that it recently completed the pharmacokinetics study of its proprietary intranasal spray formulation for the treatment of opioid overdose, which showed favorable results, similar to the ones for the current standard of intramuscular administration of naloxone. Naloxone, according to the Company, has been used in opioid overdose management for more than 40 years. It works by rapidly displacing the intoxicating opioids from the brain’s opioid receptors, reversing the clinical signs of opioid overdose. Naloxone was first approved in the US in 1971, as Narcan injection to reverse opioid intoxication and overdose.
Last Close Stock Review
At the close of trading session on Monday, October 09, 2017, INSYS Therapeutics’s stock price declined 2.26% to end the day at $8.66. A total volume of 615.60 thousand shares were exchanged during the session, which was above the 3-month average volume of 564.71 thousand shares. At Monday’s closing price, the stock’s net capitalization stands at $645.43 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily